Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation reports developments across medical technology, patient monitoring and connected care. Company updates commonly center on Masimo SET pulse oximetry, noninvasive measurements, sensors, patient monitors, Masimo Hospital Automation and Masimo SafetyNet platforms, and telehealth or telemonitoring applications used in hospital and care settings.
Recurring MASI news also includes clinical evidence for monitoring performance, operating and financial results, non-GAAP financial materials, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. The company’s public updates reflect its focus on healthcare monitoring technologies following the completed disposition of its consumer audio business.
Masimo reported strong financial results for the first quarter of 2024 with consolidated revenue at $492.8 million, including healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. GAAP net income per diluted share was $0.35 and Non-GAAP net income per diluted share was $0.77. The company saw improvements in gross margins in healthcare and is increasing guidance for healthcare revenues and EPS for 2024. Masimo also announced plans to separate its consumer business.
Masimo, a global leader in monitoring technologies, received FDA clearance for Stork™, an over-the-counter baby monitoring system for infants up to 18 months. The system provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature without a prescription. It offers visual and audible alarms if readings fall outside preset ranges, utilizing advanced pulse oximetry technology. Stork is available at major retailers and online, with additional alarm features through a mobile app update. Stork features a sleek design, patented SET® sensor technology, and a camera with future AI-based features. It is FDA-cleared for OTC use, suitable for infants and neonates in home environments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.